Cramer Rosenthal Mcglynn LLC decreased its stake in Omnicell, Inc. (NASDAQ:OMCL) by 1.9% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 303,050 shares of the company’s stock after selling 5,990 shares during the quarter. Cramer Rosenthal Mcglynn LLC’s holdings in Omnicell were worth $14,698,000 at the end of the most recent reporting period.
Other institutional investors also recently made changes to their positions in the company. Marco Investment Management LLC purchased a new position in shares of Omnicell in the 3rd quarter worth approximately $231,000. Stevens Capital Management LP purchased a new position in shares of Omnicell in the 3rd quarter worth approximately $305,000. Stone Ridge Asset Management LLC purchased a new position in shares of Omnicell in the 4th quarter worth approximately $360,000. USA Financial Portformulas Corp purchased a new position in shares of Omnicell in the 4th quarter worth approximately $364,000. Finally, Sei Investments Co. boosted its holdings in shares of Omnicell by 76.7% in the 3rd quarter. Sei Investments Co. now owns 8,219 shares of the company’s stock worth $420,000 after purchasing an additional 3,567 shares during the period.
Omnicell, Inc. (OMCL) opened at $44.55 on Wednesday. Omnicell, Inc. has a 1-year low of $37.90 and a 1-year high of $55.40. The company has a current ratio of 1.73, a quick ratio of 1.28 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1,766.58, a price-to-earnings ratio of 267.94, a P/E/G ratio of 3.76 and a beta of 0.75.
A number of brokerages have recently commented on OMCL. Piper Jaffray Companies lifted their target price on Omnicell from $38.00 to $44.00 and gave the stock a “neutral” rating in a report on Friday, February 2nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $60.00 target price on shares of Omnicell in a report on Wednesday, December 13th. Oppenheimer reiterated a “buy” rating and issued a $55.00 target price on shares of Omnicell in a report on Tuesday, December 5th. Zacks Investment Research cut Omnicell from a “hold” rating to a “sell” rating in a report on Wednesday, January 10th. Finally, Craig Hallum cut Omnicell from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $56.14.
In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of Omnicell stock in a transaction on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the sale, the chief financial officer now directly owns 40,544 shares of the company’s stock, valued at approximately $2,095,719.36. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Chairman Randall A. Lipps sold 8,186 shares of Omnicell stock in a transaction on Tuesday, March 6th. The shares were sold at an average price of $44.21, for a total value of $361,903.06. Following the sale, the chairman now directly owns 224,206 shares of the company’s stock, valued at $9,912,147.26. The disclosure for this sale can be found here. 3.77% of the stock is owned by insiders.
Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.